Immuron Limited (AU:IMC) has released an update.
Immuron Limited’s CEO, Steven Lydeamore, will be presenting at the TechKnow Invest Roadshow in Melbourne, which will also be available via live stream for broader accessibility. The Australian biopharmaceutical company specializes in orally delivered antibodies for infectious diseases, with their product Travelan® designed to prevent travelers’ diarrhea. Additionally, Immuron is advancing IMM-529, a treatment for recurrent Clostridioides difficile infection, showcasing their innovative immunotherapy platform.
For further insights into AU:IMC stock, check out TipRanks’ Stock Analysis page.
